GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Scaled Net Operating Assets

Gland Pharma (NSE:GLAND) Scaled Net Operating Assets : N/A (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Gland Pharma's operating assets for the quarter that ended in Mar. 2024 was ₹85,699 Mil. Gland Pharma's operating liabilities for the quarter that ended in Mar. 2024 was ₹15,652 Mil. Gland Pharma's Total Assets for the quarter that ended in Dec. 2023 was ₹0 Mil. Therefore, Gland Pharma's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was N/A.


Gland Pharma Scaled Net Operating Assets Historical Data

The historical data trend for Gland Pharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Scaled Net Operating Assets Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.66 0.71 0.61 0.54 0.80

Gland Pharma Quarterly Data
Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gland Pharma's Scaled Net Operating Assets

For the Drug Manufacturers - General subindustry, Gland Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Scaled Net Operating Assets falls into.



Gland Pharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Gland Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2024 )
=(Operating Assets (A: Mar. 2024 )-Operating Liabilities (A: Mar. 2024 ))/Total Assets (A: Mar. 2023 )
=(85698.8-15652.37)/87775.35
=0.80

where

Operating Assets(A: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=106612.46 - 20913.66
=85698.8

Operating Liabilities(A: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=19374.03 - 1412.19 - 2309.47
=15652.37

Gland Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2024 )
=(Operating Assets (Q: Mar. 2024 )-Operating Liabilities (Q: Mar. 2024 ))/Total Assets (Q: Dec. 2023 )
=(85698.8-15652.37)/0
=N/A

where

Operating Assets(Q: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=106612.46 - 20913.66
=85698.8

Operating Liabilities(Q: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=19374.03 - 1412.19 - 2309.47
=15652.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gland Pharma Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Gland Pharma (NSE:GLAND) Business Description

Traded in Other Exchanges
Address
Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines